Subscribe
Sign in
Home
Archive
Leaderboard
About
What Comes After the GLP-1 Hype?
It's messy, unglamorous stuff involving patients and insurers and crystal balls for pharma
Sep 28
•
Ashwin Sharma, MD
17
5
Latest
Top
Discussions
When GLP-1s become brain drugs
Doors are opening for Alzheimer's patients, for Novo, and for... Regeneron?
Sep 14
•
Ashwin Sharma, MD
28
3
Why Novo Nordisk and Eli Lilly Won't Compete on Price
But they will compete on market access and launch success
Sep 1
•
Ashwin Sharma, MD
20
5
The $100 Billion Overreaction
how do oral GLP-1s expand the market?
Aug 24
•
Ashwin Sharma, MD
16
Why Britain’s GLP-1 Patients Are Paying for America’s Drug Politics
1.5 million become collateral damage
Aug 17
•
Ashwin Sharma, MD
11
2
Why Novo Nordisk is Out of Options (Except One)
patents become weapons
Aug 5
•
Ashwin Sharma, MD
36
23
Are GLP-1s About to Kill the Alcohol Industry?
Change is definitely coming, but not in the way you think
Jul 13
•
Ashwin Sharma, MD
14
GLP-1s Are Quietly Killing Your Cravings (and Maybe Your Bad Habits Too)
New brain-imaging studies reveal these meds may silence the impulse engine driving addiction, compulsive behaviours, and billion-dollar snack aisles
Jul 6
•
Ashwin Sharma, MD
95
8
See all
GLP-1 Digest
The GLP-1 newsletter for founders, operators and investors.
Subscribe
Recommendations
The Argument
Jerusalem Demsas
The Gut Group
Dr Arif Hussenbux MBBS
Big Pharma Sharma
Big Pharma Sharma
In-Network
David Ohta
GLP-1 Digest
Subscribe
About
Archive
Recommendations
Sitemap
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
